BioCentury
ARTICLE | Company News

PTC reveals price of steroid for DMD

May 8, 2017 10:56 PM UTC

PTC Therapeutics Inc. (NASDAQ:PTCT) lost $1.46 (12%) to $10.79 on Monday after it revealed plans for its impending launch of Duchenne muscular dystrophy drug Emflaza deflazacort, including its price.

As it reported 1Q17 earnings, the company said it intends to launch Emflaza "in the coming weeks" at an anticipated net price of $35,000 for a 25 kg patient. It forecast 2017 Emflaza sales of $5-$10 million...